2 results about "Caspase activity" patented technology

A method of treating neurodegenerative diseases using hUCB plasma is presented herein. hUCB plasma attenuated the hyperactive response (Group III) and potentiated the normal response in Group I ALS patients, but did not alter that of the non-responders to PHA (Group II). The elevated activity of caspase 3 / 7 observed in the MNCs from ALS patients was significantly reduced by hUCB plasma treatment. The ability of hUCB plasma to modulate the mitogen cell response and reduce caspase activity suggest that the use of hUCB plasma alone, or with stem cells, may prove useful as a therapeutic in ALS patients. hUCB plasma was shown to increase therapeutic efficacy of MNCs as well as decrease apoptosis of MNCs. The cytokine profile of hUCB plasma supports its usefulness as a sole therapeutic as well as an additive to MNCs.

A method for treating or reducing the severity of neurodevelopmental defects in a developing nervous system after exposure to an anesthetic by modulating or inhibiting caspase activity, for example, by administering a pan-caspase inhibitor such as pan-caspase inhibitor Q-VD-OPh to a subject having or at risk of congestive heart disease and / or having a ciliopathic disorder.